COVID-19 Articles

Epidemiology

Article Journal Authors Findings
How will country-based mitigation measures influence the course of the COVID-19 epidemic? The Lancet Anderson et al. Overview of epidemiology, measures to slow transmission.
Aerosol and surface stability of HCoV-19 (SARS-CoV-2) compared to SARS-CoV-1 medRxiv Doremalen et al. The median half-life estimate for HCoV-19 is ~13 hours on steel and ~16 hours on polypropylene.

Clinical Features

Article Journal Authors Findings
Clinical Characteristics of Coronavirus Disease 2019 in China NEJM Guan et al. Clinical characteristics of patients in Wuhan, China
Coronavirus Disease 2019 (COVID-19): Role of Chest CT in Diagnosis and Management Li, Xia AJR Chest CT findings.

Genetics

Article Journal Authors Findings
The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 Nature Microbiology Coronaviridae Study Group of the Internation Committee on Taxonomy of Viruses Naming, Coronavirus Taxonomy

Pharmaceuticals

Under Investigation

Drug Mechanism of Action Trials
Chloroquine Increases endosomal pH, interferes with glycosylation of ACE2 Multiple: NCT04261517
Favipiravir Inhibits RNA dependent RNA polymerase (RdRp)
Interferon alfa-2b Signal transduction through type I interfereon --> downstream antiviral effects
Remdesivir Nucleoside analog Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment
Ritonavir + Lopinavir Protease inhibitor
Sarilumab Blocks IL-6 signaling
Tocilizumab Blocks IL-6 signaling

Vaccine Development

Company Vaccine Type Clinical Trial Stage
Moderna mRNA Phase I

Pharmaceutical Literature

Article Journal Authors Findings
Coronavirus puts drug repurposing on the fast track Nature Biotechnology Harrison Brief overview of repurposing drugs for COVID-19
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 NEJM Cao et al. In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir–ritonavir treatment beyond standard care.
Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19 NEJM Vaduganathan et al. Data currently too limited. Effects uncertain.
Hopkins: Coronavirus Cases Map